Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection

Status Recruiting

Clinical Trial Summary

The overall objective of the study is to evaluate the safety and efficacy of MSC therapy combined with best supportive care in hospitalized patients with COVID-19.

Clinical Trial Description

This study is a monocentric prospective phase I/II clinical trial, aiming at evaluating the safety and efficacy of 3 intravenous administrations of BM-MSC in 20 patients with severe to critical COVID-19 pneumonia. After signed informed consent, patients will receive 3 infusions of (1.5)-3.0 x106/kg BM-MSC (from the same donor) at 3-4 days interval, in addition to the standard of care for COVID-19 disease. The trial will be open for inclusion for 2 years after initiation. Each patient will be followed for 90 days after inclusion. The total study duration will thus be 2 years and 90 days. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04445454
Study type	Interventional
Source	University of Liege
Contact	Yves Beguin, MD,PhD
Phone	(0032)43667201
Email	yves.beguin@chuliege.be
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	June 12, 2020
Completion date	September 30, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04369456` - Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients	N/A
Completed	`NCT04527471` - Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19	Phase 2
Recruiting	`NCT04410510` - P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19	Phase 2/Phase 3
Withdrawn	`NCT04383899` - Role of Ibuprofen and Other Medicines on Severity of Coronavirus Disease 2019
Completed	`NCT04542915` - COVID-19-Related Health and Practices Among Dental Hygienists
Not yet recruiting	`NCT04400019` - Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM)	Phase 2/Phase 3
Completed	`NCT04532632` - Taste and Smell Impairment in Critically Ill COVID-19 Patients
Suspended	`NCT04385771` - Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation	N/A
Terminated	`NCT04954014` - Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients	Phase 2
Terminated	`NCT04530448` - Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization	Phase 4
Completed	`NCT04413435` - Clinical Characteristics of Critically Ill Patients With COVID-19
Terminated	`NCT05593770` - International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response	Phase 2/Phase 3
Completed	`NCT04510493` - Canakinumab in Patients With COVID-19 and Type 2 Diabetes	Phase 3
Active, not recruiting	`NCT04587219` - The Study of "Gam-COVID-Vac" Vaccine Against COVID-19 With the Participation of Volunteers of 60 y.o and Older	Phase 2
Withdrawn	`NCT05430958` - Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers	Phase 1
Completed	`NCT04596579` - SARS-CoV-2 (COVID-19) Immune Surveillance Among a Population Based Sample of Adults in Florida
Completed	`NCT04405934` - COG-UK Project Hospital-Onset COVID-19 Infections Study	N/A
Enrolling by invitation	`NCT04484025` - SPI-1005 Treatment in Moderate COVID-19 Patients	Phase 2
Terminated	`NCT04442230` - NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)	Phase 2
Terminated	`NCT04642638` - Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure	Phase 2/Phase 3